Sartorius Stedim Biotech Introduces Fully Integrated Upstream Platform

The platform combines an expression system with equipment and process controls to enable rapid development and scale-up of robust titers.
Sep 01, 2016
By BioPharm International Editors

Sartorius Stedim Biotech, a supplier of biopharmaceutical manufacturing products and services, announced that it has developed a fully integrated technology platform to meet the requirements of upstream bioprocessing. Covering all steps from cell-line development to commercial manufacturing processes, the platform combines an expression system with equipment and process controls to enable rapid development and scale-up of robust titers.

According to Sartorius Stedim Biotech, this platform can help biomanufacturers cut development timelines, with products reaching the clinic in 14 months.

The royalty-free Chinese Hamster Ovary expression platform of the company’s subsidiary Cellca delivers the titers required to meet cost of goods objectives. Cellca can establish a research cell bank for clients within four months.

The automated ambr15 micro bioreactor system is capable of controlling 24 or 48 micro bioreactor experiments. The system accelerates clone selection and scales up readily to Biostat STR single-use bioreactors, which biomanufacturers have successfully implemented at pilot and GMP production scales.

Sartorius Stedim Biotech has also integrated more than 100 assays from BioOutsource into its platform to facilitate rapid testing and analysis of biosimilar products.

Source: Sartorius Stedim Biotech

native1_300x100
lorem ipsum